MDACC Study No:2011-0036 ( NCT No: NCT00906945)
Title:Chemosensitization with Plerixafor Plus G-CSF
in Relapsed or Refractory Acute Myeloid Leukemia
Principal Investigator:Marina Konopleva
Treatment Agent:Cytarabine; Etoposide; G-CSF; Mitoxantrone; Plerixafor
Study Status:Closed
Study Description:The goal of the first phase of this clinical research study is to learn the
highest tolerable dose of plerixafor that can be given with G-CSF and the
standard of care chemotherapy drugs mitoxantrone, etoposide, and cytarabine

Plerixafor is designed to cause blood cells (blasts) to move out of the bone
marrow and into the blood stream where MEC may attack and kill the cancer cells.

MEC is commonly used in the treatment of AML. In this study, G-CSF is given to
help plerixafor to drive leukemic cells from the bone marrow.

Once the first phase of the study is completed, the second phase of the study
will determine whether the combination of plerixafor with G-CSF and MEC can be
more effective in treating leukemia than MEC alone.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:Cytarabine
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Genzyme
Washington University Schoold of Medicine
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Marina Konopleva
For Clinical Trial Enrollment:713-794-1628
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults